UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

3	
FORM 6-K	
REPORT OF FOREIGN PRIVATE ISSUER	
PURSUANT TO RULE 13a-16 OR 15d-16	
UNDER THE SECURITIES EXCHANGE ACT OF 1	934
For the Month of January 2019	
Commission File Number: 001-38281	
ERYTECH Pharma S.A. (Translation of registrant's name into English)	
Bâtiment Adénine, 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office)	
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Fo	orm 40-F:
☑ Form 20-F □ Form 40-F	

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): □

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): □

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

ERYTECH Pharma S.A. (the "<u>Company</u>") is submitting this Report on Form 6-K to furnish its (i) unaudited interim condensed consolidated statements of financial position as of June 30, 2018 and (ii) unaudited interim condensed consolidated statements of income (loss) for the six months ended June 30, 2018, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K.

EXHIBIT LIST

Exhibit	<u>Description</u>
99.1	Unaudited Interim Condensed Consolidated Statements of Financial Position as of December 31, 2017 and June 30, 2018
99.2	Unaudited Interim Condensed Consolidated Statements of Income (Loss) for the Six Months Ended June 30, 2017 and 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ERYTECH Pharma S.A.

Date: January 4, 2019 By: /s/ Eric Soyer

Name Eric Soyer

Title: Chief Financial Officer and Chief Operating Officer

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Amounts in thousands of euros)

	1	As of	
	June 30, 2018	December 31, 2017	
	€	€	
ASSETS			
Non-current assets			
Intangible assets	1,629	53	
Property, plant and equipment, net	2,759	3,406	
Other non-current financial assets	852	234	
Total non-current assets	5,241	3,693	
Current assets			
Inventories	259	176	
Trade and other receivables		76	
Other current assets	11,237	5,791	
Cash and cash equivalents	165,421	185,525	
Total current assets	176,916	191,568	
TOTAL ASSETS	182,156	195,261	
		<u> </u>	
		As of	
LIABILITIES AND SHAREHOLDERS' EQUITY	June 30, 2018 €	December 31, 2017 €	
Shareholders' equity	C	C	
Share capital	1,794	1,794	
Premiums related to share capital	281,745	281,785	
Reserves	(100,567)	(68,346)	
Translation reserve	(190)	(203)	
Net loss for the period	(18,970)	(33,530)	
			
Total shareholders' equity	163,812	181,419	
Non-current liabilities			
Long-term provisions	322	214	
Financial liabilities – non-current portion	1,630	2,019	
Deferred tax		3	
Total non-current liabilities	1,952	2,236	
Current liabilities	700	00.4	
Financial liabilities – current portion	796	824	
Trade and other payables	12,366	8,076	
Other current liabilities	3,231	2,706	
Total current liabilities	16,392	11,606	
	<u> </u>		
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	182,156	195,261	

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (Amounts in thousands of euros, except per share amounts)

Six Months Ended June 30,

	Julie 30,	
	2018	2017
	€	€
Operating income		
Revenues		
Other income	2,265	1,788
Total operating income	2,265	1,788
Operating expenses		
Research and development	(16,752)	(12,082)
General and administrative	(7,393)	(3,895)
Total operating expenses	(24,145)	(15,977)
Operating loss	(21,880)	(14,189)
Financial income	2,966	160
Financial expenses	(42)	(47)
Financial income	2,924	114
Income tax	(14)	(5)
Net loss	(18,970)	(14,081)
Basic / diluted loss per share (€/share)	(1.06)	(1.42)